Sarepta Therapeutics, Inc. (SRPT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Sarepta Therapeutics, Inc. reported revenue of $2.20B, up 15.6% from the prior year. The company ran a net loss, with a net margin of -32.5%. It held $3.35B in total assets against $2.21B in total liabilities.
Key ratios (FY2025)
-31.8%
Operating margin
-32.5%
Net margin
-62.5%
Return on equity
+15.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933.01M | $701.89M | $540.10M | $380.83M | $301.03M | $154.58M | $5.42M |
| Cost of Revenue | $25.50M | — | — | — | — | — | — | — | — | — |
| Operating Income | -$699.78M | $218.08M | -$267.82M | -$536.20M | -$459.71M | -$564.16M | -$705.56M | -$343.63M | -$171.64M | -$266.73M |
| Net Income | -$713.41M | $235.24M | -$535.98M | -$703.49M | -$418.78M | -$554.13M | -$715.08M | -$361.92M | -$50.69M | -$267.26M |
| EPS (Diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | — | — | — | — |
| Total Assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B | $1.82B | $1.64B | $1.31B | $424.10M |
| Total Liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B | $1.00B | $609.80M | $518.75M | $87.41M |
| Shareholders' Equity | $1.14B | $1.53B | $859.34M | $384.95M | $928.01M | $761.76M | $818.19M | $1.03B | $789.22M | $336.69M |
| Cash & Equivalents | $801.28M | $1.10B | $428.43M | $966.78M | $2.12B | $1.50B | $835.08M | $370.83M | $599.69M | $122.42M |
| Operating Cash Flow | -$205.48M | -$205.79M | -$500.99M | -$325.35M | -$443.17M | $107.47M | -$456.46M | -$388.66M | -$232.00M | -$245.82M |
| Capital Expenditures | $101.97M | $136.96M | $76.11M | $30.82M | $38.49M | $82.20M | $59.63M | $61.16M | $12.00M | $5.34M |
| Shares Outstanding | 104.96M | 96.90M | 93.73M | 87.95M | 87.13M | 79.37M | 75.18M | 71.07M | 64.79M | 54.76M |